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Abstract 
Review on TP53, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
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Location: 17p13.1 
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7659779) 
Probe(s) - Courtesy Mariano Rocchi, Resources for 
Molecular Cytogenetics 
Note 
For complete information and data, see:  the novel 
TP53 website and  UMD TP53 Mutation Database 
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Diagram of the TP53 gene. Exons are represented by boxes with numbers and sizes inside. Intron sizes (not drawn to scale) are 
also indicated. Translated exons for the canonical TP53 protein (393 aa) are shown in light green, in red for isoforms beta and in 
blue for isoforms gamma. 
 
DNA/RNA 
Description 
The TP53 gene spans a region of 32,772 bp. The 
protypical TP53 gene is composed of 11 exons. Two 
novel alternatively spliced exons localized in intron 
9 have been identified (exons 9β and 9γ). 
To solve some confusing situation on TP53 
nomenclature, an international consortium has 
joined forces with the Locus Reference Genomic 
(LRG) consortium to provide a stable reference 
sequence and a coordinate system for permanent and 
unambiguous reporting of disease-causing variants 
in genes related to any pathology. The TP53 
nomenclature can be reached at 
http://ftp.ebi.ac.uk/pub/databases/lrgex/LRG_321.x
ml. 
Transcription 
The transcription of the TP53 is highly complex and 
can vary between tissue and/or cellular context. 
Different p53 mRNA variants are expressed through 
the use of alternative splicing and an internal 
promoter in intron 4. 
Protein 
Description 
At least, 12 TP53 isoforms are expressed but the full-
length protein (TP53 p1 or TP53α is always the 
major species detected in every tissue. The p1 
protein contains from N-term to C-term, two 
transactivationg domains (TAD1, 1-40 and TAD2, 
41-61), a proline rich domain (63-97), a specific 
DNA binding domain (102-292), 3 nuclear 
localization signals (305-322), a tetramerization 
domain that includes a nuclear export signal (325-
355) and a negative regulatory domain (360-393). 
Shorter C-terminal TP53 isoforms do not contain 
either the tetramerization domain or the negative 
regulatory domain. Shorter N-terminal TP53 
isoforms do not contain TAD1 (Δ40 TP53 isoforms), 
TAD1, TAD2 and the proline rich domain (Δ133) or 
TAD1, TAD2, the proline rich domain and part of 
the DNA binding domain (Δ160) 
 
Diagram of TP53α, the major TP53 protein expressed in normal cells. TAD1: transactivation domain 1; TAD2: transactivation 
domain 2; Pro: proline- rich domain; DBD: DNA binding domain; NES: nuclear exclusion signal: NLS: nuclear localization signal; 
Oli: oligomerization domain; C-ter: carboxy-terminus domain. I to V correspond to the five highly conserved domains of the 
protein. 
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Domains in the various TP53 isoforms. TAD1: transactivation domain 1; TAD2: transactivation domain 2; Pro: proline- rich 
domain; NES: nuclear exclusion signal: NLS: nuclear localization signal; Oli: oligomerization do- main; C-ter: carboxy-terminus 
domain. 
The LRG nomenclature used for TP53 protein (p1 to p13) and RNA (t1 to t8) is also shown on the right. 
 
 
 
Pathway i) the stress signals activate the pathway; ii) the upstream mediators detect and interpret the upstream signals; iii) the 
core regulation of TP53 is disrupted leading to TP53 accumulation and activation; iv) the downstream events, mainly 
transcriptional activation or protein-protein interaction v) The final outcome. 
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Response Gene 
Apoptosis APAF1 ; BAX - FAS - - MIR34A - PMAIP1 ; TP53AIP1 - PERP -PIDD1 - TP53I3 - BBC3 
- SIVA1 ; TNFS10 
Growth arrest YWHAZ ; BTG2 ; CDKN1A - GADD45A ; MIR34A ; MIR34B / MIR34C ; Prl13; PTPRVP 
; RPRM  
Senescence CDKN1A ; SERPINE1 ; PML l 
DNA repair Dbd2; ERCC5 ; FANCC ; GADD45A ; XRCC5 ; MGMT ; MLH1 ; MSH2 ; RRM2B ; 
PAPD7 ; XPC  
Metabolism / Anti 
oxydant 
ADORA2B ; ALDH4A1 ; PRKAB1 ; GAMT ; GLS2 ; SLC2A1 (-);SLC2A4  (-);GPX1 ; 
IGFBP3 ; LPIN1 ; PARK2 ; VCAN (-); PRKAB1 ID:44100 ; PRKAB2 ; ten; SCO1 ; SESN1 
; SESN2 ; TIGAR ; TP53INP1 ;  
Autophagy ATG10 ; ATG2B ; ATG4A ; ATG4C ; ATG7 ; CTSD ; DDIT4 ; DRAM1 ; RBFOX3 ; 
LAPTM4A ; STK11 ; PIK3R3 ; PRKAG2 ; BBC3 ; ACD ; TSC2 ; ULK1 ; ULK2 ; UVRAG 
; VAMP4 ; VMP1  
Tumour micro 
environment 
ADGRB1 ; CX3CL1 ; ICAM1 ; IRF9 ; ISG15 ; SERPINB5 ; CCL2 ; NCF2 ; SERPINE1 ; 
TLR1 - TLR10 ; PRSS55 ; ULBP1 ; ULBP2  
Invasion 
metastasis 
CDKN1A ; MIR34A ; MIR200C  
Stem cell biology CDKN1A ; MIR145 ; MIR34A ; MIR34B / MIR34C ; NOTCH1  
TP53 regulation CARD16 ; MDM2 , PIRH-2; TP63 , TP73  
Unknown* APOBEC3H; HRAS ; TNFAIP8 ; ZMAT3  
This list is not exhaustive. Several TP53 responses overlap and include identical genes. Adapted from Bieging et al. with 
modifications. 
* Genes induced by TP53 without any clear relation to a specific pathway 
 
TP53 is modified by numerous post-translational 
modifications phosphorylation, acetylation, 
ubiquitination, sumoylation, neddylation, 
methylation, ADP ribosylation, and glycosylation. 
Acetylation of multiple residues is essential for TP53 
activation and DNA transcriptional activity. 
Function 
The transcription factor TP53 is at the centre of a 
network that integrates and transmits multiple 
signals generated during various stress events to 
ensure cell and tissue homeostasis. This network also 
includes the two other members of the TP53 family, 
TP63 and TP73 as well as the two negative 
regulators, MDM2 and MDM4 (MDMX). 
The p53 response can be conveniently divided into 
two sets of pathways acting upstream and 
downstream the core regulation of TP53. 
The upstream pathways (stress signal detection and 
integration)  
Multiple type of stress such as DNA damage, 
hypoxia, nucleotides pool depletion, viral infection, 
oncogene activation or oxidative stress can elicit a 
TP53 response. For each stress, a different panel of 
mediators is recruited. 
In most cases, the goal of this step is the disruption 
of the TP53-MDM2 interaction leading to an 
accumulation and an activation of the TP53 protein.  
Subsequent post translational modifications 
(phosphorylation and acetylation principally) 
modulate TP53 activity depending of the type and 
the intensity of the damage and the cellular context. 
For DNA damage, the ATM and CHEK2 kinase will 
phosphorylate TP53, MDM2 and MDM4 to release 
the negative regulation of the regulatory proteins. 
For ribosomal stress, free ribosomal proteins will 
bind and sequester MDM2, relieving its inhibitory 
For oncogene activation (hyperproliferative stress), 
the P16-ARF protein will sequester MDM2 in the 
nucleolus and relieve its inhibitory activity. 
The core regulation of TP53 
In normal tissues, TP53 protein levels are maintained 
at a very low level predominantly by the action of 
specific E3 ligases such as MDM2 and the ubiquitin 
proteosome pathway.  
Other E3 ligases such as Pirrh2, RFWD2 or TRIM24 
target TP53 and able to regulate its stability. 
TP53 translation is also highly regulated and 
enhanced after various types of stress.  
TP53 mRNA includes two Internal Ribosome Entry 
Sites (IRESs) elements.  
The first IRES is located in the 5'UTR of the full-
length isoform, the second is located into the protein-
coding region and mediates the translation  
 
of a ΔN-p53 isoform. 
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The downstream pathways (effectors activation and 
TP53 response)  
Several thousand genes have been shown to be 
activated by TP53 upon various types of stress. 
Different sets of genes are associated with a specific 
response. Initially, apoptosis, growth arrest and 
senescence have been considered to be the main 
response to TP53 activation.  
More recent studies have emphasized the importance 
of TP53 in other cellular responses such as DNA 
repair, metabolism and regulation of the Warburg 
effect, autophagy and regulation of stemm cell 
maintenance. 
Although growth arrest, apoptosis and senescence 
were originally associated with the tumour 
suppressor activity of TP53, their importance has 
recently been challenged. Several mouse models 
defective for these three T53 activities lack any 
predisposition to develop neoplasia. 
TP53 also has cytoplasmic transcription-
independent functions (apoptosis and autophagy) via 
a direct interaction with pro- and anti-apoptotic 
factors in mitochondria. 
Expression 
Widely expressed. 
Localisation 
Nucleus 
Mutations 
Germinal 
Germline TP53 mutations are associated with Li-
Fraumeni (LFS) and Li-Fraumeni-like syndromes 
(LFL), characterized by a familial clustering of 
tumours, with a predominance of soft tissue and 
bone sarcomas, breast cancers, brain tumours, and 
adrenocortical carcinomas, diagnosed before the age 
of 45 years.  
TP53 germline mutations have also been observed in 
families at high risk of breast cancer, albeit at very 
low frequency.  
A founder mutation TP53 
(NG_017013.2:g.21852G#62A, p.R337H) is 
detected in 0.3% of the general population in 
southern Brazil. This mutation is associated with an 
increased risk of childhood adrenal cortical 
carcinoma (ACC) but is also common in Brazilian 
LFS/LFL families.  
The frequency of TP53 de novo germline mutation 
ranges between 7 and 20%. 
Somatic 
Mutation of the TP53 gene can be found in 50% of 
human cancer.  
More than 80% of TP53 mutations are missense 
mutations that lead to the synthesis of a stable 
oncogenic protein that accumulates in the nucleus of 
tumour cells. The frequency of TP53 alterations 
range from less than 5% in cervical carcinoma to 
90% in ovarian carcinoma or Small Cell Lung 
Cancer (SCLC) but these numbers must be taken 
with caution due to several factors such as the 
subtype of the cancer (lung or breast cancer), the 
stage of the tumour (prostate carcinoma or chronic 
lymphocytic leukaemia) and exogenous features 
such as viral or bacterial infection.  
Two international consortiums have reported the 
sequencing of more than 10.000 tumour genomes 
and confirmed that the TP53 gene is the most 
frequently mutated gene in human cancer. TP53 
mutations are strongly associated with tumours with 
high chromosomal instability.  
Cancer specific driver genes can be noticed: APC in 
colorectal carcinoma (violet); VHL in kidney cancer 
(green) or PTEN and PIK3CA in endometrial 
carcinoma (green and red)  
Molecular epidemiology studies demonstrate a link 
between exposure to various types of carcinogens, 
specific mutational events in the TP53 gene and the 
development of specific cancers.  
Lung cancer 
TP53 mutations in lung cancer are mostly GC to TA 
transversions, with a rate of transition mutations 
lower than in other cancers. There is a strong 
correlation between the frequency of these GC to TA 
transversions and lifetime cigarette smoking. This 
high frequency of GC to TA transversions has not 
been detected for other cancers such as colon, breast, 
ovary or brain cancer, which are not directly 
associated with smoking. This observation is 
compatible with the role of exogenous carcinogens 
such as benzo(a)pyrene in lung cancer. After 
metabolic activation, one of the derivative products 
of benzo(a)pyrene, the prime carcinogen in cigarette 
smoke, binds predominantly to guanine and gives 
rise to specific G-C to T-A transversions. Exposure 
of cells to benzo(a)pyrene lead to the formation of 
adducts at codon 157, 248 and 273 in the p53 gene. 
These positions are the major mutational hotspots in 
human lung cancer but not in other cancers. The p53 
gene is one of the targets of carcinogens found in 
tobacco.  
Liver cancer 
There is a strong association between infection with 
hepatitis B virus and hepatocellular carcinoma. 
Aflatoxin B1 has been considered to be a significant 
etiological factor for liver cancer in Western Africa 
and Asia. Aflatoxins are compounds produced by 
fungal strains (such as Aspergillus flavus for 
aflatoxins B1) that are known food contaminants in 
these countries. Aflatoxins are highly carcinogenic 
in experimental animals, producing liver tumours in 
newborn mice, rats, fish, ducks and monkeys.  
Worldwide epidemiological studies showed that a 
specific mutation at codon 249 (c.747G>T, 
p.R249S) is specifically found in liver cancer from 
countries in which food was contaminated by 
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aflatoxin B1. In countries which do not consume 
contaminated food (including Europe and the USA), 
TP53 mutations are scattered along the central part 
of p53, as for the other types of cancer. In vitro and 
in vivo analysis showed a specific binding of 
aflatoxin B1 to codon 249 of the TP53 gene.  
Bladder cancer 
Aristolochic acid (AA), a common ingredient in 
many Chinese herbs, is a powerful nephrotoxin and 
human carcinogen associated with chronic kidney 
disease and upper urinary tract urothelial carcinomas 
including bladder cancer. AA exposure is also 
associated with Balkan endemic nephropathy (BEN) 
similarly characterized by kidney failure and a high 
frequency of transitional cancer of urothelial tracts 
including bladder, renal pelvis and ureters.  
TP53 mutation from patients exposed to AA display 
a high frequency A:T-to-T:A transversions, a 
mutational signature associated with AA which 
forms a covalent adduct with adenine that leads to 
this transversion.  
Skin cancer  
Ultraviolet (UV) light induces specific DNA damage 
such as cyclobutane pyrimidine dimers (CPDs) and 
pyrimidine(6-4)pyrimidine photoproducts (64PPs) 
at dipyrimidine sites, where two pyrimidine (Py) 
bases are juxtaposed in tandem in the nucleotide 
sequence of DNA. If left unrepaired, this lesion leads 
to specific types of mutation: base substitutions of 
cytosine (C) → thymine (T) at dipyrimidine sites and 
CC → TT tandem base substitutions. These two 
types of mutation are called UV signature and their 
detection suggests past exposure to UV. In skin 
cancer such as squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC), the frequency of TP53 
is high (70 to 80%) with more than 15% of tandem 
mutations (less than 1% for other cancer types).  
Colorectal or brain cancer  
The cytosine-guanine (CpG) dinucleotide is a 
hotspot for pathological mutations in the human 
genome. This hypermutability is due to its role as the 
major site of cytosine methylation with the attendant 
risk of spontaneous deamination of 5-
methylcytosine (5mC) to yield C → T and G → A 
transitions. Most TP53 hotspots for mutations in 
colorectal or brain cancer are located at CpG sites 
with a mutation spectrum compatible with 5-
methylcytosine deamination. These hotspot codons, 
CGN at positions 175, 248 or 273, encode arginine 
residues important for TP53 structure and/or 
activity. It is interesting to note that arginine can also 
be encoded by AGG and AGA that have the same 
frequency of usage in human but are not targeted by 
methylation. It has not yet been determined whether 
or not there is a specific selection to keep CGN in the 
TP53. 
Implicated in 
Skin cancers  (non melanoma) 
Disease 
Non melanoma skin cancers are the most common 
form of cancer, globally accounting for at least 40% 
of human cancer. About 80% are basal-cell cancers 
(BCC) and 20% squamous-cell cancers (SCC). Most 
skin cancer cases are caused by exposure to 
ultraviolet radiation from the sun. 
Prognosis 
Patients with primary cutaneous SCC or BCC have 
a very good prognosis. 
Oncogenesis 
The hedgehog signalling pathway (HH pathway) is 
the primary target in BCC with mutations in PTCH1, 
SMO or SFU. TP53 mutations are found in 60% of 
BCC. In SCC, the frequency of TP53 mutation varies 
between 40 to 80% depending on the aggressivity of 
the tumour or the seuqnecing methodology. Deep 
sequencing allows the detection of multiple 
subclones with different TP53 mutations.  
The pattern of TP53 mutations in skin cancer is 
highly related to UV exposure. 
Skin cancers (Melanoma) 
Disease 
Case per year (thousands) 132; death per year 
(thousands) 31. Melanoma is a skin tumours 
characterized by the malignant growth of 
melanocytes. The incidence is continuing to increase 
worldwide and UV exposure is a known risk factor 
for melanoma. Epidemiologic data suggest that 
gender and genetics may influence the distribution of 
melanoma on the body surface and histopathologic 
characteristics of the lesion. 
Oncogenesis 
The MAPK pathway is the primary target in 
melanoma with mutations in BRAF1 (50%) or 
NRAS (20%). TP53 gene mutations are rare in 
melanoma (5%) but the apoptotic function of the 
protein is often impaired. Melanoma often loses  , a 
cell-death effector that acts with cytochrome c and 
CASP9 to mediate p53-dependent apoptosis. It may 
contribute to the low frequency of TP53 mutations 
observed in this highly chemoresistant tumour type. 
Alteration of CDKN2A in 30% of melanoma could 
also contribute to TP53 deficiency. 
Lung cancers 
Disease 
Case per year (thousands) 1,825; death per year 
(thousands) 1,590 (Worldwide ranks, cases / deaths:  
1/1). There are 2 main types of lung cancer: about 
10% to 15% are small cell lung cancer (SCLC) and 
85% to 90% arenon-small cell lung cancer 
(NSCLC). There are several subtypes of NSCLC, 
Adenocarcinoma (50%), Squamous cell carcinoma 
(30%); Large cell carcinoma (15%) and other 
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(includes carcinoid and neurodendocrine tumours) 
(5%). 
Oncogenesis 
In SCLC, recent studies using Novel Generation 
Sequencing showed that TP53 mutations can be 
found in 95% of the cases. In NSCLC, the frequency 
of TP53 mutations varies among the subtypes. The 
frequency of TP53 mutations is the highest in 
squamous cell carcinomas (70 to 80%) and lower in 
adenocarcinomas (50%). Lung cancer from smokers 
shows a distinct, unique TP53 mutation spectrum 
with G to T transversions at codons 157, 158, 179, 
248, and 273, which is uncommonly observed in 
lung cancer from non-smokers or in cancer unrelated 
to tobacco smoking such as colorectal or brain 
tumours. 
Breast cancer 
Disease 
Case per year (thousands) 1,677; death per year 
(thousands) 522 (Worldwide ranks, cases / deaths: 
2/5). Breast carcinoma is a heterogeneous disease 
with multiple subtypes defined either histologically 
or more recently via gene expression. 
Oncogenesis 
In Triple Negative Breast Cancer (TNBC, 10-15% of 
breast cancer with low or lack of expression of 
estrogen (ER) and progesterone (PR) receptors, lack 
of human epidermal growth factor receptor 2 (HER2 
) over-expression and a worse prognostic), the 
frequency of TP53 is high (80%). 
Molecular profiling studies have identified four 
major subtypes of breast cancer: luminal A, luminal 
B, basal like, and HER2. The frequency of TP53 
alteration in these subtypes ranges from 12% in 
luminal A, 30% in luminal B, 70% in HER2 to more 
than 80% in basal like. There is a partial overlap 
between TNBC and Basal like. 
Colorectal cancers 
Disease 
Case per year (thousands) 1,360; death per year 
(thousands) 693 (Worldwide ranks, cases / deaths: 
3/4). CRC is a heterogeneous disease classically 
divided into three sub-types  
(i) Chromosomal instability (CIN) characterized by 
microsatellite stable tumours (MSS), loss of 
heterozygosity and major chromosomal changes in 
tumour-suppressor genes and oncogenes (60% of 
CRC)  
(ii) The CpG island methylator phenotype (CIMP) 
which causes transcriptional silencing by 
methylation of CpG-rich regions in the promoter of 
tumour-suppressor genes (10 to 15% of CRC).  
(iii) Microsatellite instability (MSI) is characterized 
by the accumulation of frame shift mutations in 
microsatellite sequences due to a deficiency in 
mismatch repair (MMR) genes (10 to 15% of CRC) 
Cytogenetics 
MSI tumour are generally characterized by diploid 
or near-diploid cells 
Oncogenesis 
The most frequently mutated genes in CRC are 
KRAS, APC and TP53. 
Prostate cancer 
Disease 
cases per year (thousands): 1,112; deaths per year 
(thousands): 307 (Worldwide ranks, cases / deaths: 
4/8). Prostate carcinoma is characterized by a high 
genetic and clinical heterogeneity with multiple 
subclones. 
Oncogenesis 
TP53 mutations are infrequent in primary disease 
and are mostly found in patients with metastatic 
disease 
Gastric cancer 
Disease 
cases per year (thousands): 952 ; deaths per year 
(thousands): 723 (Worldwide ranks, cases / deaths: 
5/3). Risk factors for gastric cancer include: 
Helicobacter pylori gastric infection, advanced age, 
male gender, diet including dry salted foods, 
atrophic gastritis, pernicious anemia, cigarette 
smoking, Menetrier's disease , and familial 
polyposis. Adenocarcinoma histology accounts for 
90% to 95% of all gastric malignancies. The 
prognosis of patients with gastric cancer is related to 
tumour extent and includes both nodal involvement 
and direct tumour extension beyond the gastric wall. 
Tumour grade may also provide some prognostic 
information. 
Oncogenesis 
TP53 is the most frequently mutated gene in gastric 
carcinoma with a frequency ranging between 40 and 
60%. 
Liver cancer 
Disease 
cases per year (thousands): 782 ; deaths per year 
(thousands): 746 (Worldwide ranks, cases / deaths: 
6/2).  Most patients with HCC (70 to 90%) have an 
established background of chronic liver disease and 
cirrhosis, with major risk factors for developing 
cirrhosis including chronic infection with hepatitis B 
virus (HBV), hepatitis C virus (HCV), Alcoholism, 
and nonalcoholic steatohepatitis (NASH). 
Additional risk factors include intake of aflatoxin-B1 
contaminated food (China and West Africa), 
diabetes, obesity, certain hereditary conditions such 
as hemochromatosis, and some metabolic disorders. 
Cytogenetics 
Losses of 1p, 4q, 5p, 5q, 8q, 13q, 16p, 16q, and 17p 
in 20 to 50% of cases. 
Oncogenesis 
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Somatic mutations in the TERT (coding for 
telomerase reverse transcriptase) promoter is the 
most frequent genetic alteration in hepatocellular 
carcinoma (HCC).  
These mutations created a potential binding site for 
ETS transcription factors and are predicted to 
increase promoter activity and TERT transcription.  
Mutated genes in HCC are TP53, beta-catenin 
(CTNNB1 ) and ARIDA1. TP53 mutations are more 
frequent in patients associated with HBV infection 
compared to those associated with alcoholism.  
The frequency and the pattern of TP53 mutations in 
HCC show a high geographical variation depending 
on HBV infection prevalence or aflatoxin 
consumption.  
In areas of high aflatoxin exposure, 50% of HCC 
cases bear a specific AGG to AGT point mutation in 
codon 249 of the p53 tumour suppressor gene. A 
second mutation at codon 157 is also frequent albeit 
at lower frequency. Exposure of cells to aflatoxin B1 
leads to the formation of adducts at codon 249 in the 
p53 gene. 
Cervical cancer 
Disease 
Cases per year (thousands): 527 ; deaths per year 
(thousands): 265 (Worldwide ranks, cases / deaths: 
7/10). Almost all cervical cancers are caused by HPV 
(human papilloma virus). There are more than 100 
types of HPV, of which at least 13 are cancer-
causing (also known as high-risk type) including 
HPV16 and 18. 
Oncogenesis 
The UBE3A (E6) oncoprotein produced by the high-
risk type of HPV stimulates ubiquitinylation and 
proteasome-dependent degradation of the tumour 
suppressor p53 via the formation of a trimeric 
complex comprising E6, p53, and E6-AP. TP53 
mutation is therefore very infrequent in cervical 
cancer. 
Oesophagus cancers 
Disease 
Case per year (thousands) 455; death per year 
(thousands) 400 (worldwide ranks 8/6) There are 
two main types of esophageal carcinoma, squamous 
cell carcinoma and adenocarcinoma. Most 
adenocarcinomas arise in Barrett esophagus that 
develops in response to chronic gastroesophageal 
reflux. 
Oncogenesis 
The frequency of TP53 mutation is high in both 
types, ADC and SCC, and can reach 70%. TP53 
mutations are an early event in ADC as it can be 
found in Barrett esophagus. 
Bladder cancer 
Disease 
Case per year (thousands) 429; death per year 
(thousands) 165 (worldwide ranks 9/12). 
Prognosis 
Highly variable, according to the stage and the grade. 
Cytogenetics 
-9, -11 or del(11p), del(17p) and LOH at 17p, 
del(13q), frequent other LOH, aneuploidy, 
polyploidy, complex karyotypes. 
Oncogenesis 
TP53 mutation are found in 40 to 50% of bladder 
carcinoma. Three variants are particularly frequent 
in bladder cancer: c.853G>A; p.E285K, c.839G>C; 
p.R280T and c.839G>A; p.R280K. 
Pancreatic cancer 
Disease 
Case per year (thousands) 338; death per year 
(thousands) 330 (worldwide ranks 12/7); Pancreatic 
cancers are divided into two major subtypes: 
adenocarcinoma (95% of cases), and rare endocrine 
tumours often designated as neuroendocrine 
tumours. 
Prognosis 
Pancreatic cancer is one of the most deadly of all 
types of cancer. 
Oncogenesis 
KRAS mutation is the most frequent genetic 
variation in pancreatic adenocarcinoma (95%) 
followed by TP53 mutation (60-70%) and CDKN2A 
deletion (50%). 
Head and neck squamous cell 
carcinoma 
Disease 
Head and neck cancer encompasses malignant 
tumours arising within the upper aerodigestive tract.  
The major etiologic agents are tobacco and alcohol 
consumption and for some cases human papilloma 
virus (HPV) infection. More than 90% of head and 
neck cancers are squamous cell carcinomas, which 
originate from the mucosal surfaces of the lip and 
oral cavity, nasopharynx, oropharynx, hypopharynx, 
and larynx. 
Oncogenesis 
TP53 mutation can be found in about 60 to 70% of 
HPV positive HNSCC cancers. The frequency is 
lower in HPV negative tumours (less than 10%) 
Ovary carcinoma 
Disease 
Case per year (thousands) 238; death per year 
(thousands) 152 (worldwide ranks 18/13). Based on 
histopathology, immunohistochemistry, and 
molecular genetic analysis, at least five main types 
of ovarian carcinomas are identified: high-grade 
serous carcinomas (HGSCs; 70%), endometrioid 
carcinomas (EC; 10%), clear-cell carcinomas (CCC; 
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10%), mucinous carcinomas (MC; 3%), and  LGSC 
(<5%). These tumours account for 98% of ovarian 
carcinomas. 
Oncogenesis 
In HGSC, the frequency of TP53 mutation reaches 
95% and is the most frequent genetic alteration in 
this subtype. 
sarcoma 
Disease 
Osteosarcoma is a primary bone malignancy with a 
particularly high incidence rate in children and 
adolescents relative to other age groups. 
Oncogenesis 
Mutation of RB1, located at chromosome 13q14.2 
and TP53 are frequent in osteosarcoma. Deletion or 
rearrangement of the TP53 gene can reach 20% and 
are not found in other cancer types. 
Brain Tumours 
Disease 
Case per year (thousands) 256; death per year 
(thousands) 189 (worldwide ranks 17/11) 
Glioblastoma (GBM), also known as glioblastoma 
and grade IV astrocytoma, is the most common and 
most aggressive form and represent 15% of brain 
tumours. There are two subtypes of GBM: de novo 
(new or primary) and secondary. De novo tumours 
are the most common (90%) and are very aggressive. 
Secondary GBM (10%) typically start as low-grade 
or mid-grade astrocytoma and eventually transform 
into malignant, rapidly growing GBM. 
Oncogenesis 
TP53 mutation is an early and frequent (over 60%) 
event in secondary glioblastomas while it is rare in 
primary glioblastomas (less than 10%). Primary 
glioblastomas display a high frequency of mdm2 
amplification which is mutually exclusive to TP53 
mutations. Isocitrate dehydrogenase 1 ( IDH1) 
mutations are frequent in secondary glioblastomas 
(60-70%) and seems to co-occur with TP53 
mutations. 
Chronic lymphocytic leukaemia (CLL) 
Disease 
Chronic lymphocytic leukaemia (CLL) represents 
the most common leukaemia in the Western world;  
it accounts for ~40% of all adult leukaemia's. 
Prognosis 
TP53 mutations are associated with a poor response 
to therapy. 
Cytogenetics 
CLL patients have acquired chromosomal 
abnormalities such as: deletion 13q; deletion 11q; 
trisomy 12 and deletion 17p 
Oncogenesis 
TP53 mutations are infrequent in the early phase of 
the disease and are mostly found in patients in 
progressive disease or with relapse/refractory 
disease.  
CLL is one of the few cancers where TP53 status is 
used to for therapeutical decision. 
Non-Hodgkin lymphoma 
Disease 
Follicular lymphoma (FL) and diffuse large B-cell 
lymphoma (DLBCL) are the two most common non-
Hodgkin lymphomas (NHLs). 
Prognosis 
TP53 mutation is an independent marker of poor 
prognosis in patients with diffuse large B-cell 
lymphoma (DLBCL) treated with 
cyclophosphamide, hydroxydaunorubicin, 
vincristine, and prednisone (CHOP) therapy 
Oncogenesis 
Both FL and DLCBL are characterized by a high 
frequency of mutations in genes associated with 
chromatin modification such as KMT2D /MLL2.  
Frequency of TP53 mutation in DLBCL range 
between 20 and 80%.  
This large range is due to the heterogeneity of the 
various cohorts as TP53 mutations are more frequent 
in patients with refractory DLBCL. 
Burkitt lymphoma 
Disease 
Burkitt lymphoma (BL) is an uncommon form of 
aggressive lymphoma.  
Three subtypes of Burkitt lymphoma are recognized: 
the endemic form, occurring primarily in Africa and 
associated with the Epstein-Barr virus (EBV); the 
sporadic form, representing less than 3 % of all non-
Hodgkin lymphomas (NHL); and the 
immunodeficiency-associated form, occurring 
primarily in HIV-infected patients. 
Oncogenesis 
BL is characterized by chromosomal translocations 
leading to the overexpression of myc.  
The most common rearrangement is 
t(8;14)(q24;q32), which accounts for most cases and 
involve MYC and .  
Other frequently mutated genes are ID3, ARID1A, 
SMARCA4 and TP53 which is inactivated in 40 to 
50% of BL. 
Myelodysplastic syndromes 
Disease 
Myelodysplastic syndromes (MDS) describe a 
heterogeneous group of bone marrow disorders that 
predominate in the elderly. These patients present 
with a dysplastic bone marrow morphology and 
variable cytopenias, and they have an increased risk 
of transformation to acute myeloid leukaemia 
(AML) 
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Oncogenesis 
The frequency of TP53 mutation in MDS is low but 
associated with a poor prognosis. 
Acute myeloid leukaemia 
Disease 
Acute myeloid leukemia (AML) is a biologically 
heterogeneous disease that can be classified into 3 
distinct groups: secondary AML (s-AML) represents 
transformation of an antecedent diagnosis of 
myelodysplastic syndrome (MDS) or myelo-
proliferative neoplasm (MPN), therapy-related AML 
(t-AML) develops as a late complication in patients 
with prior exposure to therapies, and de novo AML 
arises in the absence of an identified exposure or 
prodromal stem cell disorder. 
Oncogenesis 
The most frequently mutated gene in AML are 
FLT3, NPM1 and  DNMT3A. The frequency of 
TP53 mutation does not exceed 10% in de novo 
AML. In t-AML or s-AML, the frequency of TP53 
mutation can reach 30% and is associated with a poor 
prognosis. 
Li-Fraumeni syndrome (LFS) 
Disease 
Autosomal dominant condition, cancer-prone 
disease, Li-Fraumeni syndrome (LFS) is defined by 
the existence of a proband with early onset sarcoma 
and a first degree relative with cancer before 45 
years, plus another first/second degree relative with 
cancer at before 45 years or sarcoma at any age.  
Other extended criteria have been proposed to 
provide better guidelines for TP53 genetic testing:  
Birch definition : (1) a proband with any childhood 
cancer or sarcoma, brain tumour, or adrenocortical 
carcinoma diagnosed before age 45 years and (2) a 
first- or second-degree relative with a typical Li-
Fraumeni cancer (sarcoma, breast cancer, brain 
tumour, adrenocortical carcinoma, or leukaemia) at 
any age and (3) a first- or second-degree relative with 
any cancer before age 60 years.  
Eels definition: Two first- or second-degree relatives 
with Li-Fraumeni-related malignancies (sarcoma, 
breast cancer, brain tumour, leukaemia, 
adrenocortical tumour, melanoma, prostate cancer, 
pancreatic cancer) at any age.  
Chompret definition: A proband who has (1) a 
tumour belonging to the Li-Fraumeni tumour 
spectrum (soft-tissue sarcoma, osteosarcoma, 
premenopausal breast cancer, brain tumour, 
adrenocortical carcinoma, leukemia, or 
bronchoalveolar lung cancer) before age 46 years 
and (2) at least one first- or second-degree relative 
with a Li-Fraumeni tumour (except breast cancer if 
the proband has breast cancer) before age 56 years or 
with multiple tumours or a proband with multiple 
tumours (except multiple breast tumours), 2 of which 
belong to the Li-Fraumeni tumour spectrum and the 
first of which occurred before age 46 years or A 
proband who is diagnosed with adrenocortical 
carcinoma or choroid plexus tumours, irrespective of 
family history. 
Prognosis 
Most common cancer in Li-Fraumeni children 
(before the age of 10 years) are: soft tissue sarcoma, 
brain tumours and adrenocortical carcinomas; 
osteosarcoma predominates in adolescents; 
afterwards, female breast cancer, soft tissue 
sarcomas and brain tumours prevail, and other less 
frequent cancers such as leukemias or colon 
carcinomas are also observed. Multiple primary 
cancers are quite characteristic of Li- Fraumeni 
syndrome but may also be representative of Bloom's 
syndrome. Cancers in this disease, as in other cancer-
prone diseases, often occur early in life: 50% of 
patients aged 30 years have had a cancer (i.e. 
penetrance is 50%, according to this disease 
definition), and penetrance is 90% at age 60 years. 
Oncogenesis 
Approximately 70% of families with LFS have a 
mutation in the TP53 gene. Most of these variants are 
missense mutations similar to those found in 
colorectal carcinoma with a high frequency of 
mutations at CpG dinucleotides. 
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